Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Perha Pharmaceuticals logo — From Sea to Pharmacy

Perha Pharmaceuticals

From Sea to Pharmacy

Founded 2019 France France 12 employees Grant Total: $2.80M Biopharma, Biotechnology +2

General Information

Company Name Perha Pharmaceuticals
Founded Year 2019
Location France France +1
Founders / Decision Makers
Team member
Employees 12
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Grant
Social

Get notified when Perha Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Perha Pharmaceuticals

Perha Pharmaceuticals is a biotech company focusing on the development of innovative, low molecular weight kinase inhibitors to address cognitive disorders associated with Down syndrome (DS) and Alzheimer's disease (AD), as well as hearing loss induced by ototoxic products. Founded in April 2019 by Dr. Laurent MEIJER and Dr. Philippe de LAVENNE, the company has garnered attention with its groundbreaking research. Notably, Dr. Meijer's expertise in the study of protein kinases and their inhibitors at CNRS adds a strong research foundation to the startup. With a focus on two main programs, Perha Pharma aims to correct cognitive deficits associated with Down syndrome by targeting the DYRK1A protein kinase. They have identified pharmacological inhibitors derived from Leucettamine B, extracted from the Leucetta microraphis marine sponge, which have shown promise in preclinical studies. Additionally, the company is working on preventing hearing loss induced by ototoxic drugs or noise, and has received a €2.50M grant investment at 23 March 2022 from the European Innovation Council to support its pioneering research. Being headquartered in France, Perha Pharmaceuticals not only demonstrates potential in addressing critical unmet medical needs but also exhibits a strong foundation for sustained growth in the Biopharma, Biotechnology, and Health Care industries. With its compelling research focus and recent investment, Perha Pharmaceuticals is poised to make significant strides in addressing these challenging health conditions.

Taxonomy: biotech enterprise, kinase inhibitors, pharmaceutical research, cognitive impairments, Down syndrome, Alzheimer's disease, ototoxic-induced hearing loss, neuroscience, pharmaceutical industry

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
23 Mar 2022
Seed Round •••••• 2
Investor Investor
23 Mar 2022
Debt Financing •••••• 1
Investor
28 Nov 2021

FAQ About Perha Pharmaceuticals

From Sea to Pharmacy
Perha Pharmaceuticals was founded in 2019.
Perha Pharmaceuticals is headquartered in France.
Perha Pharmaceuticals operates in the following industries: Biopharma, Biotechnology, Health Care, Life Sciences.
Perha Pharmaceuticals has approximately 12 employees.
Perha Pharmaceuticals has completed 3 funding rounds, raising a total of $2.80M. The latest funding stage is Grant.

We're actively collecting intelligence on Perha Pharmaceuticals.

Track Perha Pharmaceuticals to get notified

Don't just browse. Track.

Signal Tracker monitors Perha Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy